Drugs used in Alzheimer's disease and neuroplasticity

Clinical Therapeutics

Volumn 19, Issue 1, 1997, Pages 4-15

  Allain, Hervé ^a,e   Bentue Ferrer, Daniele ^a   Gandon, Jean Marc ^b   Le Doze, Francois ^c   Belliard, Serge ^d  

^a Institute of Electronics and Telecommunicalions of Rennes   (France)

^b Biotrial SA   (France)

^c CHU CÔTE DE NACRE   (France)

^d RENNES UNIVERSITY HOSPITAL   (France)

^e UNIVERSITÉ DE RENNES 1   (France)

Author keywords

Alzheimer's disease; clinical trials; pharmacology; plasticity; tacrine

Indexed keywords

1,2,3,4 TETRAHYDRO 1 METHYL 8 (2 MORPHOLINYLMETHOXY)QUINOLINE; AGOMELATINE; CEBARACETAM; CHOLINESTERASE INHIBITOR; GINKGO BILOBA EXTRACT; MINAPRINE; MOCLOBEMIDE; NEUROTROPIC AGENT; PIRIBEDIL; TACRINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CLINICAL TRIAL; DEMENTIA; DRUG MECHANISM; DRUG RESEARCH; DRUG USE; HUMAN; MEMORY; PATHOPHYSIOLOGY; PLASTICITY; REVIEW;

EID: 0030896501     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(97)80068-9     Document Type: Article

References (74)

1. Cotman CW, Anderson AJ. A potential role for apoptosis in neurodegeneration and Alzheimer's disease. Mol Neurobiol. 1995;10:19-44.
2. Lo AC, Houenou LJ, Oppenheim RW. Apoptosis in the nervous system: Morphological features, methods, pathology and prevention. Arch Histol Cytol. 1995; 58:139-149.
3. Allain H, Belliard S, De Certaines J, et al. Potential biological targets for anti-Alzheimer drugs. Dementia. 1993;4: 347-352.
4. Berg L, Morris JC. Diagnosis. In: Terry RD, Katzman R, Bick KL, eds. Alzheimer's Disease. New York, NY: Raven Press; 1994:9-25.
5. Allain H, Belliard S, Michel O, et al. La maladie d'Alzheimer: Questions thérapeutiques du moment. Lett Pharmacol (Paris). 1996;10:10-13.
6. Weytingh MD, Bossuyt PMM, Van Crevel H. Reversible dementia: More than 10% or less than 1%. A quantitative review. J Neurol. 1995;242:466-471.
7. Smith MA, Sayre LM, Monnier VM, et al. Radical ageing in Alzheimer's disease. Trends Neurosci. 1995; 18:172-176.
8. Coleman PD. Possible pharmacological approaches to slowing down Alzheimer's disease progression. Neurobiol Aging. 1995;16:873-876.
9. Lahiri DK, Lewis S, Farlow MR. Tacrine alters the secretion of the beta-amyloid precursor protein in cell lines. J Neurosci Res. 1994;37:777-787.
10. Stolerman IP, Mirza NR, Shoaib M. Nicotine psychopharmacology: Addiction, cognition and neuroadaptation. Med Res Rev. 1995;15:47-72.
11. Delbarre B, Delbarre G, Rochat C, et al. Effect of piribedil, a D2 dopaminergic agonist on dopamine, amino-acids and free radicals in the gerbil brain after cerebral ischemia. Mol Chem Neuropathol 1995; 26:43-52.
12. Lange KW, Rausch WD, Gsell W, et al. Neuroprotection by dopamine agonists. J Neural Transm. 1994;43(Suppl):183-201.
13. Caldwell M, Reymann JM, Bentué-Ferrer D, et al. Dopamine agonists lisuride and piribedil protect against behavioural and histological changes following 4-vessel occlusion in the rat. Neuropsychobiology. 1996;34:117-124.
14. Ghosh A, Greenberg ME. Calcium signaling in neurons: Molecular mechanisms and cellular consequences. Science. 1995; 268:239-247.
15. Williams LR. Oxidative stress, age-related neurodegeneration, and the potential for neurotrophic treatment. Cerebrovasc Brain Metab Rev. 1995;7:55-73.
16. Kisilevsky R. Antiamyloid drugs. Potential in the treatment of diseases associated with aging. Drugs Aging. 1996;8:75-83.
17. Koliatsos VE, Price DL, Clatterbuck RE, et al. Neurotrophic strategies for treating Alzheimer's disease: Lessons from basic neurobiology and animal models. Ann New York Acad Sci. 1993;695:292-299.
18. Miller RG, Petajan JH, Bryan WW, et al. A placebo-controlled trial of recombinant human ciliary neurotrophic (rh CNTF) factor in amyotrophic lateral sclerosis. Ann Neurol. 1996;39:256-260.
19. Robakis NK. Molecular biology of Alzheimer's disease pathology. J Neuropathol Exp Neurol. 1995;(Suppl):16S-17S.
20. Allain H, Bentue-Ferrer D, Belliard S. Aspects thérapeutiques et prise en charge. Traitements pharmacologiques de la maladie d'Alzheimer. In: Hérisson Ch, Touchon J, Enjalbert M, eds. La Maladie d'Alzheimer et Médecine de Rééducation. Paris, France: Masson; 1996:127-141.
21. Mohr E, Feldman H, Gauthier S. Canadian guidelines for the development in antidementia therapies: A conceptual summary. Can J Neurol Sci. 1995;22:62-71.
22. Allain H, Bernard PM, Dartigues JF, et al. Point de vue sur la méthodologie des essais de médicaments à visée cognitive chez les sujets âgés. L'Encéphale. 1994; 20:725-739.
23. Checler F. Processing of the β-amyloid precursor protein and its regulation in Alzheimer's disease. J Neurochem. 1995; 65:1431-1444.
24. Roth GS, Joseph JA, Mason P. Membrane alterations as causes of impaired signal transduction in Alzheimer's disease and aging. Trends Neurosci. 1995;18:203-205.
25. Rose SPR. Cell-adhesion molecules, glucocorticoids and long-term memory formation. Trends Neurosci. 1995;18:502-505.
26. Disterhof J, Thompson LT, Weiss C, et al. The calcium hypothesis for Alzheimer's disease: Insights from animal and human studies. Neurosci Res Commun. 1995;12: 121-131.
27. Strimmatter WJ, Roses AD. Apolipoprotein E and Alzheimer's disease. Annu Rev Neurosci. 1996;19:53-77.
28. Blain H, Merched A, Visvikis S, et al. Maladie d'Alzheimer: Hypothèses impliquant les apolipoprotéines E. Presse Med. 1996;25:763-768.
29. Rose RJ. Genes and human behavior. Annu Rev Psychol. 1995;46:625-654.
30. Dewji NN, Singer SJ. Genetic clues to Alzheimer's disease. Science. 1996;271: 159-160.
31. Rahmann H. Brain gangliosides and memory formation. Behav Brain Res. 1995;66: 105-116.
32. 2+-binding protein ALG-2 and Alzheimer's disease gene ALG-3. Science. 1996;271:521-525.
33. Polvikoski T, Sulkava R, Haltia M, et al. Apolipoprotein E, dementia and cortical disposition of β-amyloid protein. NEJM. 1995;333:1242-1247.
34. Shimohama S, Matsushima H. Signal transduction mechanisms in Alzheimer disease. Alzheimer Dis Assoc Disord. 1995;9(Suppl 2):15-22.
35. Cowburn RF, O'Neill C, Fowler CJ. Membrane alterations in Alzheimer's disease and aging. Trends Neurosci. 1995;18: 483-484.
36. Araujo DM, Lapchak PA, Meaney MJ, et al. Effects of aging on nicotinic and muscarinic autoreceptor function in the rat brain: Relationship to presynaptic cholinergic markers and binding sites. J Neurol Sci. 1990;10:3069-3078.
37. Whitehouse PJ, Martino AM, Antuono PG, et al. Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Res. 1986;371:146-151.
38. Snaedal J, Johannesson J, Jonsson JE, et al. The effects of nicotine in dermal plaster on cognitive functions in patients with Alzheimer's disease. Dementia. 1996;7: 47-52.
39. Gitelman DR, Prohovnik I. Muscarinic and nicotinic contributions to cognitive functions and cortical blood flow. Neurobiol Aging. 1992;13:313-318.
40. Sherwood N. Effects of cigarette smoking on performance in a simulated driving task. Neuropsychobiology. 1995;32:161-165.
41. Allain H. Les phases précoces de développement des médicaments dans la maladie d'Alzheimer. In: Michel B, Soumireux-Mourat B, Dubois B, eds. Système Limbique et Maladie d'Alzheimer. Marseille, France: Solal; 1996:157-165.
42. Soares JC, Gershon S. THA-historical aspects, review of pharmacological properties and therapeutic effects. Dementia. 1995;6:225-234.
43. Minthon L, Nilsson K, Edvinsson L, et al. Long term effects of tacrine on regional cerebral blood flow changes in Alzheimer's disease. Dementia. 1995;6: 245-251.
44. Homeyer P. La tacrine: Bilan et perspectives après un an d'utilisation. Neuro-Psy (Paris). 1996;10:2-8.
45. Eagger SA, Richards M, Levy R. Long term effects of tacrine in Alzheimer's disease: An open study, Int J Geriatr Psychiatry. 1994;9:643-647.
46. Knopman D, Schneider L, Davis K, et al. Long-term tacrine (Cognex®) treatment: Effect on nursing home placement and mortality. Neurology. 1996;47:166-177.
47. Mega MS, Cummings JL, Fiorello J, et al. The spectrum of behavioral changes in Alzheimer's disease. Neurology. 1996;46: 130-135.
48. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the allele for apolipoprotein E. NEJM. 1996;334: 752-758.
49. Lawlor BA. Behavioral complications in Alzheimer's disease: Clinical practice series. Washington, DC: American Psychiatric Press; 1995:31.
50. Geinisman Y, Detoledo-Morrell L, Morrell F, et al. Hippocampal markers of agerelated memory dysfunction: Behavioral, electrophysiological and morphological perspectives. Prog Neurobiol. 1995;45: 223-252.
51. Schmand B, Jonker C, Hooijer C, et al. Subjective memory complaints may announce dementia. Neurology. 1996;46: 121-125.
52. Tierney MC, Szalai JP, Snow WG, et al. A prospective study of the clinical utility of Apo E genotype in the prediction of outcome in patients with memory impairment. Neurology. 1996;46:149-154.
53. Butters N, Delis DC. Clinical assessment of memory disorders in amnesia and dementia. Annu Rev Psychol. 1995;46:493-523.
54. Allain H, Lieury A, Belliard S, et al. Effect of drugs on mnestic performance: A methodological approach. Hum Psychopharmacol. 1996;11:11-19.
55. Lieury A, Germain R, Menard G, et al. Etude de corrélations entre autoestimation de la mémoire, test psychométrique (SM9) et test de la mémoire de la vie quotidienne. Therapie. 1996;51:155-162.
56. Patterson MB, Mack JL, Geldmacher DS, et al. Executive functions and Alzheimer's disease: Problems and prospects. Eur J Neurol. 1996;3:5-15.
57. Sano M, Rosen W, Stern Y, et al. Simple reaction time as a measure of global attention in Alzheimer's disease. J Intern Neuropsychol Soc. 1995;1:56-61.
58. Guiraud P. Psychiatrie Générale. Paris: Le François; 1950.
59. Le Doze F, Baron JC, Marie RM, et al. Brain glucose utilization in a patient with athymhormia from a kindred with autosomal dominant parkinsonism and psychicdisturbances. J Neurol Neurosurg Psychiatry. 1994;57(Suppl 8):1014-1015.
60. Laplane D, Dubois B, Pillon B, et al. Perte d'autoactivation psychique et activité mentale stéréotypée par lésion frontale. Rapports avec le trouble obsesso-compulsif. Rev Neurol. 1988;14(Suppl 10):564-570.
61. Forette F, Hoover T, Gracon S, et al. A double-blind, placebo-controlled enriched population study of tacrine in patients with Alzheimer's disease. Eur J Neurol. 1995; 2:229-238.
62. Liberini P, Valerio A, Memo M, et al. Lewy-body dementia and responsiveness to cholinesterase inhibitors: A paradigm for heterogeneity of Alzheimer's disease. Trends Pharmacol Sci. 1996;17:155-160.
63. Sramek JJ, Hurley DJ, Wardle TS, et al. The safety and tolerance of xanomeline tartrate in patients with Alzheimer's disease. J Clin Pharmacol. 1995;35:800-806.
64. Allain H, Wesnes K, Neuman E, et al. Bridging study of S12024 in 53 in-patients with Alzheimer's disease. J Am Geriatr Soc. 1997;45:125-126.
65. Allain H, Guez D, Malbezin M, et al. Safety and clinical efficacy of S12024 in patients with mild to moderate Alzheimer's disease. Presented at the Fourth International Symposium on Advances in Alzheimer's Therapy; April 10-14, 1996; Nice/Springfield.
66. Seshadri S, Drachman DA, Lippa CF. Apolipoprotein E-∈4 allele and the life-time risk of Alzheimer's disease. What physicians know and what they should know. Arch Neurol. 1995;52:1074-1079.
67. Allain H, Belliard S, Le Coz F, et al. The choice of surrogate endpoints in early phases of anti-Alzheimer's drug development. Therapie. 1995;50(Suppl):28. Abstract.
68. Allain H, Raoul P, Lieury A, et al. Effect of two doses of Ginkgo biloba extract (EGb 761) on the dual-coding test in elderly subjects. Clin Ther. 1993;15: 549-557.
69. Menard G, Defrance R, Quera-Salva MA, et al. Standardization of activity monitoring for the assessment of the sleep/wake cycle in patients with cognitive impairment. Therapie. 1995;50(Suppl):163. Abstract.
70. Allain H, Lieury A, Belliard S, et al. Etude comparative en double aveugle randomisée de la minaprine 200 mg/j et du placebo sur la plainte mnésique. Therapie. 1996;51:155-162.
71. Allain H, Lieury A, Brunet-Bourgin F, et al. Antidepressants and cognition: Comparative effects of moclobemide, viloxazine and maprotiline. Psychopharmacology. 1992;106(Suppl):S56-S61.
72. Allain H, Guez D, Neuman E, et al. Safety and clinical efficacy of S12024 in patients with mild to moderate Alzheimer's disease. In: Backer R, Giacobini E, eds. Alzheimer's Disease: From Molecular Biology to Therapy. Boston: Birkhaüser; 1996:305-310.
73. Sano M, Growdon J, Thomas R, et al. Evaluation of efficacy measures in clinical trials for Alzheimer's disease: Does psychometric test performance predict clinically relevant outcomes? Neurology. 1996;46(Suppl 2):A218. Abstract.
74. Amouyel P, Neuman E, Dillemann L, et al. Characterization of the apolipoprotein E genotypes in a European multicenter trial on Alzheimer's disease with the S12024-2 (Memory Enhancer). Neurology. 1996;46(Suppl 2):A218. Abstract.